Evolving Role of Low-Molecular-Weight Heparins in ST-Elevation Myocardial Infarction

Abstract

Spanish

French

OBJECTIVE:

To review the available literature on the efficacy and safety of low-molecular-weight heparin (LMWH) in the treatment of ST-elevation myocardial infarction (STEMI) in patients treated with fibrinolytic therapy or conservative medical management.

DATA SOURCES:

A MEDLINE search (1966–March 2004) using the key words myocardial infarction, STEMI, LMWH, enoxaparin, and dalteparin identified pertinent articles. The references of these articles were reviewed for additional pertinent references.

STUDY SELECTION AND DATA EXTRACTION:

All human trials of LMWH in STEMI were evaluated. All pertinent studies were included in the review.

DATA SYNTHESIS:

LMWH did not show a benefit in STEMI without fibrinolytic therapy. Enoxaparin is similar to intravenous unfractionated heparin (UFH) in combination with nonspecific fibrinolytic therapy with regard to invasive reperfusion markers and 30-day clinical outcomes. Enoxaparin decreases composite endpoints in combination with fibrin-specific fibrinolytic therapy compared with UFH, primarily through a reduction in the incidence of reinfarction at 30 days. Bleeding rates with LMWH in combination with fibrinolytic agents are not greater than those with UFH.

CONCLUSIONS:

Enoxaparin is a reasonable alternative to UFH in patients with STEMI treated with fibrin-specific fibrinolytic therapy. LMWH in patients managed with nonspecific fibrinolytic therapy or conservative medical treatment does not provide an advantage over standard management. Large clinical trials are ongoing which will provide more definitive recommendations.

Keywords

dalteparin enoxaparin fibrinolytic agents myocardial infarction

Get full access to this article

View all access options for this article.

References

Forrester

. Toward understanding the evolution of plaque rupture. J Am Coll Cardiol 2003;42: 1566–8.

Braunwald

Antman

Beasley

Califf

Cheitlin

Hochman

ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). 2002. www.acc.org/clinical/guidelines/unstable/unstable.pdf (accessed 2004 Jan 12).

Antman

Anbe

Armstrong

Bates

Green

Hand

ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines on the Management of Patients with Acute Myocardial Infarction). 2004. http://qc.acc.org/clinical/guidelines/stemi/index.pdf (accessed 2004 Jul 12).

Cheng

JWM

. Recognition, pathophysiology, and management of acute myocardial infarction. Am J Health Syst Pharm 2001;58: 1709–21.

Mizuno

Satomura

Miyamoto

Arakawa

Shibuya

Arai

Angioscopic evaluation of coronary-artery thrombi in acute coronary syndromes. N Engl J Med 1992;326: 287–9.

MacMahon

Collins

Knight

Yusuf

Peto

Reduction in major morbidity and mortality by heparin in acute myocardial infarction (abstract). Circulation 1988;78(suppl II):II–98.

O'Donnell

Ridker

Hebert

Hennekens

. Antithrombotic therapy for acute myocardial infarction. J Am Coll Cardiol 1995;25(suppl):23S–9.

Ridker

Hebert

Fuster

Hennekens

. Are both aspirin and heparin justified as adjuncts to thrombolytic therapy for acute myocardial infarction? Lancet 1993;341: 1574–7.

Weitz

. Low molecular weight heparins. N Engl J Med 1997;337: 688–98.

10.

Wright

Kopecky

Reeder

. Update on intravenous fibrinolytic therapy for acute myocardial infarction. Mayo Clin Proc 2000;75: 1185–92.

11.

Antman

McCabe

Gurfinkel

Turpie

AGG

Bernink

PJLM

Salein

Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 11B trial. Circulation 1999;100: 1593–601.

12.

Cohen

Demers

Gurfinkel

Turpie

AGG

Fromell

Goodman

A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997;337: 447–52.

13.

Klein

Buchwald

Hillis

Monrad

Sanz

Turpie

Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease: Fragmin in unstable coronary artery disease study (FRIC). Circulation 1997;96: 61–8.

14.

Fragmin during instability in coronary artery disease (FRISC) study group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996;347: 561–8.

15.

Gruppo Italiano per lo Studio della Sopravvivenza nell ‘Infarto Miocardico’. GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 1990;336: 65–71.

16.

Third International Study of Infarct Survival (ISIS-3) Collaborative Group. ISIS-3: A randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992;339: 753–70.

17.

Collins

Peto

Baigent

Sleight

Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction. N Engl J Med 1997;336: 847–60.

18.

The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329: 673–82.

19.

The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 1997;337: 1118–23.

20.

Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: The ASSENT-2 double-blind randomised trial. Lancet 1999;354: 716–22.

21.

Rihn

Vanscoy

. Combination antithrombotic therapy in acute myocardial infarction. Am J Health Syst Pharm 2002;59: 1882–5.

22.

Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care: International Consensus on Science. The era of reperfusion: Section 1: Acute coronary syndromes (acute myocardial infarction). Circulation 2000;102:I-172–I-203.

23.

Fox

KAA

Goodman

Anderson

Granger

Moscucci

Flather

From guidelines to clinical practice: The impact of hospital and geographical characteristics on temporal trends in the management of acute coronary syndromes: The Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2003;24:1414–24.

24.

Glick

Kornowski

Michowich

Koifman

Roth

Lanaido

Reduction of reinfarction and angina with use of low-molecular-weight heparin therapy after streptokinase (and heparin) in acute myocardial infarction. Am J Cardiol 1996;77: 1145–8.

25.

Kontney

Dale

Abildgaard

Pedersen

. Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: The Fragmin in Acute Myocardial Infarction (FRAMI) study. J Am Coll Cardiol 1997;30: 962–9.

26.

Frostfeldt

Ahlberg

Gustafsson

Helmius

Lindahl

Nygren

Low molecular weight heparin (dalteparin) as adjuvant treatment to thrombolysis in acute myocardial infarction -a pilot study: Biochemical markers in acute coronary syndromes (BIOMACS II). J Am Coll Cardiol 1999;33: 627–33.

27.

Tatu-Chitoiu

Teodorescu

Capraru

Guran

Istratescu

Dan

Accelerated streptokinase and enoxaparin in ST-segment elevation acute myocardial infarction (the ASENOX study). Polish J Cardiol 2004;60: 441–6.

28.

Simoons

Krzeminska-Pakula

Alonso

Goodman

Kali

Loos

Improved reperfusion and clinical outcome with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction. Eur Heart J 2002;23: 1282–90.

29.

Baird

Menown

IBA

McBride

Trouton

Wilson

Randomized comparison of enoxaparin with unfractionated heparin following fibrinolytic therapy for acute myocardial infarction. Eur Heart J 2002;23: 627–32.

30.

Ross

Molhoek

Lundergan

Knudtson

Draoui

Regalado

Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: Second trial of Heparin and Aspirin Reperfusion Therapy (HART II). Circulation 2001;104: 648–52.

31.

Antman

Louwerenburg

Baars

Wesdorp

JCL

Hamer

Bassand

Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: Results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 trial. Circulation 2002;105: 1642–9.

32.

Wallentin

Bergstrand

Dellborg

Fellenius

Granger

Lindahl

Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study. Eur Heart J 2003;24: 897–908.

33.

The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: The ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001;358: 605–13.

34.

Wallentin

Goldstein

Armstrong

Granger

Adgey

AAJ

Arntz

Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting. Circulation 2003;108: 135–42.

35.

White

. Further evidence that antithrombotic therapy is beneficial with streptokinase: Improved early ST resolution and late patency with enoxaparin. Eur Heart J 2002;23: 1233–7.

36.

Wallentin

Dellborg

Lindahl

Nilsson

Pehrsson

Swahn

The low-molecular-weight heparin dalteparin as adjuvant therapy in acute myocardial infarction: The ASSENT PLUS study. Clin Cardiol 2001:24(suppl I):I12–4.

37.

Dubois

Belmans

Granger

Armstrong

Wallentin

Fioretti

Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated heparin, enoxaparin, or abciximab. J Am Coll Cardiol 2003;42: 1178–85.

38.

Armstrong

Wagner

Goodman

Van de Werf

Granger

Wallentin

ST segment resolution in ASSENT 3: Insights into the role of three different treatment strategies for acute myocardial infarction. Eur Heart J 2003;24: 1515–22.

39.

Sinnaeve

Antman

Ross

Hasselblad

Van de Werf

Granger

. Enoxaparin is superior to unfractionated heparin after fibrinolysis in acute myocardial infarction (abstract). Meta-analysis of ASSENT-3, HART-II and ENTIRE-TIMI-23 Trials. J Am Coll Cardiol 2003;41:334A.

40.

Theroux

Welsh

. Meta-analysis of randomized trials comparing enoxaparin versus unfractionated heparin as adjunctive therapy to fibrinolysis in ST-elevation acute myocardial infarction. Am J Cardiol 2003;91: 860–4.

41.

Raschke

Hirsh

Guidry

. Suboptimal monitoring and dosing of unfractionated heparin in comparative studies with low-molecular-weight heparin. Ann Intern Med 2003;138: 720–3.

42.

Zimmerman

Jeffries

McElroy

Horowitz

. Utility of a weight-based heparin nomogram for patients with acute coronary syndromes. Intern Med J 2003;33: 18–25.

43.

Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment Thrombolysis in Myocardial Infarction -Study 25 (EXTRACT-TIMI25). www.clinicaltrials.gov/ct/show/NCT00077792?order=11 (accessed 2004 Feb 19).

44.

Mukherjee

Topol

. The role of low-molecular-weight heparin in cardiovascular diseases. Prog Cardiovasc Dis 2002;45: 139–56.

45.

Kakkar

Iyengar

DeLorenzo

Hargreaves

Kadziola

. Low molecular weight heparin for treatment of acute myocardial infarction (FAMI): Fragmin (dalteparin sodium) in acute myocardial infarction. Indian Heart J 2000;52: 533–9.

46.

Cohen

Gensini

Maritz

Gurfinkel

Huber

Timerman

The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): A randomized trial. J Am Coll Cardiol 2003;42: 1348–56.

47.

Cohen

Gensini

Maritz

Gurfinkel

Huber

Timerman

Prospective evaluation of clinical outcomes after acute ST elevation myocardial infarction in patients who are ineligible for reperfusion therapy: Preliminary results from the TETAMI registry and randomized trial. Circulation 2003;108(suppl III):III14–21.

48.

Package insert. Lovenox (enoxaparin). Bridgewater, NJ: Aventis Pharmaceuticals Inc., revised April 2004.

49.

Moser

Kalus

. Role of low-molecular-weight heparin in invasive management of non-ST-elevation acute coronary syndromes. Ann Pharmacother 2004;38: 2094–104. DOI 10.1345/aph.1E176.